Study of TOP1630 for Dry Eye Syndrome

Summary

In subjects with Dry Eye Syndrome (DES): The primary objective of this study is to confirm the efficacy of TOP1630 0.1% Ophthalmic Solution TID OU compared to placebo treatment at Day 29 on pre-specified sign and symptom endpoints in subjects with moderate to severe DES.

Timeline

Start

2019-02-13

Primary completion

2019-05-14

Completion

2019-05-14

Drugs

Indications